AUTHOR=Shi Jie , Li Xiaoyong , Zhang Weiwei , Niu Yixin , Lin Ning , Zhang Hongmei , Ning Guang , Fan Jiangao , Qin Li , Su Qing , Yang Zhen 

TITLE=Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.664583

DOI=10.3389/fcvm.2021.664583

ISSN=2297-055X

ABSTRACT=<p><bold>Aims:</bold> To evaluate the prospective association of circulating PCSK9 levels with the cardiometabolic risk profiles (high LDL-cholesterol, high triglycerides, low HDL-cholesterol, hypertension, type 2 diabetes, and metabolic syndrome).</p><p><bold>Methods:</bold> A population-based prospective study was conducted among 7,104 Chinese individuals (age 56.2 ± 7.5 years; 32.0% men). Circulating PCSK9 levels were measured using ELISA.</p><p><bold>Results:</bold> Circulating PCSK9 levels were higher in women than men (286.7 ± 90.1 vs. 276.1 ± 86.4 ng/ml, <italic>p</italic> &lt; 0.001). And circulating PCSK9 was positively correlated with LDL-cholesterol, total cholesterol, and triglycerides both in men and women (all <italic>p</italic> &lt; 0.001). The positive correlation between PCSK9 and waist circumference, fasting glucose, insulin resistance, systolic blood pressure, diastolic blood pressure and C-reactive protein (all <italic>p</italic> &lt; 0.01) was observed in women only. According to Cox regression analysis, circulating PCSK9 was positively associated with incidence of high LDL-cholesterol both in men (HR 1.33, 95% CI 1.09–1.65, <italic>p</italic> &lt; 0.001) and women (HR 1.36, 95% CI 1.12–1.69, <italic>p</italic> &lt; 0.001). Moreover, PCSK9 was significantly associated with incident high triglycerides (HR 1.31, 95% CI 1.13–1.72, <italic>p</italic> &lt; 0.001), hypertension (HR 1.28, 95% CI 1.08–1.53, <italic>p</italic> = 0.011), type 2 diabetes (HR 1.34, 95% CI 1.09–1.76, <italic>p</italic> = 0.005), and metabolic syndrome (HR 1.30, 95% CI 1.11–1.65, <italic>p</italic> = 0.009) per SD change in women only. No statistically significant association was observed between circulating PCSK9 and incidence of low HDL-cholesterol (<italic>p</italic> &gt; 0.1).</p><p><bold>Conclusions:</bold> Elevated circulating PCSK9 was significantly associated with cardiometabolic risk factors and independently contributed to the prediction of cardiometabolic risks in women.</p>